Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human JAK1 Antibodies:
anti-Mouse (Murine) JAK1 Antibodies:
anti-Rat (Rattus) JAK1 Antibodies:
Go to our pre-filtered search.
Chicken Monoclonal JAK1 Primary Antibody for IF, IP - ABIN967842
Blesofsky, Mowen, Arduini, Baker, Murphy, Bowtell, David: Regulation of STAT protein synthesis by c-Cbl. in Oncogene 2001
Show all 5 Pubmed References
Chicken Monoclonal JAK1 Primary Antibody for IF, IP - ABIN967841
Kawazoe, Naka, Fujimoto, Kohzaki, Morita, Narazaki, Okumura, Saitoh, Nakagawa, Uchiyama, Akira, Kishimoto: Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation. in The Journal of experimental medicine 2001
Show all 5 Pubmed References
Human Polyclonal JAK1 Primary Antibody for IHC, WB - ABIN362146
Zheng, Hu, Quinn, Wang: Phosphotyrosine proteomic study of interferon alpha signaling pathway using a combination of immunoprecipitation and immobilized metal affinity chromatography. in Molecular & cellular proteomics : MCP 2005
Show all 4 Pubmed References
Human JAK1 Primary Antibody for IHC - ABIN966427
Wang, Griffin, Small, Thompson: Mechanism of Janus kinase 3-catalyzed phosphorylation of a Janus kinase 1 activation loop peptide. in Archives of biochemistry and biophysics 2003
Show all 2 Pubmed References
Human Polyclonal JAK1 Primary Antibody for IHC, WB - ABIN362702
Liu, Huang, Zeng, Chen, Huang, Guo, Liu, Xu, Mo, Li: Down-regulation of JAK1 by RNA interference inhibits growth of the lung cancer cell line A549 and interferes with the PI3K/mTOR pathway. in Journal of cancer research and clinical oncology 2011
Show all 3 Pubmed References
Porcine reproductive and respiratory syndrome virus -activated TAK-1 (show NR2C2 Antibodies) was essential for the activation of JNK (show MAPK8 Antibodies) and NF-kappaB (show NFKB1 Antibodies) pathways and IL-8 (show IL8 Antibodies) expression.
Data indicate that transmissible gastroenteritis virus (TGEV) infection activates the janus kinase signal transducer and activator of the transcription 1 (JAK (show JAK3 Antibodies)-STAT1 (show STAT1 Antibodies)) signaling pathway.
Data show that proinflammatory cytokines induction was ERK1/2 (show MAPK1/3 Antibodies) and JNK1 (show MAPK8 Antibodies)/2 dependent.
These data suggest that the p38 (show MAPK14 Antibodies) and JNK (show MAPK8 Antibodies) signaling pathways play pivotal roles in PRRSV replication and may regulate immune responses during virus infection.
based on the data, we can conclude that JNK (show MAPK8 Antibodies) plays an active role in fragmentation of pig oocytes and that p38 MAPK (show MAPK14 Antibodies) is not involved in this process
Retinal ischemia-reperfusion alters expression of mitogen-activated protein kinases, particularly ERK1/2 (show MAPK1/3 Antibodies), in the neuroretina and retinal arteries.
PP2A (show PPP2R2B Antibodies) and AIP1 (show PDCD6IP Antibodies) cooperatively induce activation of ASK1 (show MAP3K5 Antibodies)-JNK (show MAPK8 Antibodies) signaling and vascular endothelial cell apoptosis.
Phorbol 12-myristate 13-acetate activation of ERK (show MAPK1 Antibodies) and JNK (show MAPK8 Antibodies) signaling is relevant in the regulation of gene expression during follicular development, ovulation, and luteinization.
This is the first report of the genetic polymorphisms of the JAK1 and STAT3 (show STAT3 Antibodies) genes and their associations with the incidence of non-specific digestive disorder in rabbits.
Study provides evidence that JAK1/2 loss-of-function mutations are a genetic mechanism of lack of reactive PD-L1 (show CD274 Antibodies) expression and response to interferon gamma (show IFNG Antibodies), leading to primary resistance to PD-1 (show PDCD1 Antibodies) blockade therapy.
This study demonstrates that the nuclear import of JAK1 is essential for the optimal fitness of ABC (show ABCB6 Antibodies) DLBCL cells.
JAK1 rs11576173 and rs1497056 genotypes were significantly related to severe necroinflammatory activity (NIA) grade of chronic hepatitis C patients.
Multiple myeloma cells over express JAK1/2 and suggest combined chemotherapy with ruxolitinib, bortezomib and lenalidomide to inhibit JAK (show JAK3 Antibodies)/STAT (show STAT1 Antibodies) pathway.
Mechanistic investigations reveal that AJUBA (show AJUBA Antibodies) specifically binds the FERM domain of JAK1 to dissociate JAK1 from the IFNgamma recepter, resulting in an inhibition of STAT1 (show STAT1 Antibodies) phosporylation and concomitantly its nuclear translocation. Clinically, the level of AJUBA (show AJUBA Antibodies) in CRC (show CALR Antibodies) specimens is negatively correlated with the levels of IFIT2 (show IFIT2 Antibodies) and pSTAT1
Multilevel genomic analyses of microsatellite instability+ colorectal cancer revealed molecular heterogeneity with clinical relevance, including tumor immunogenicity and a favorable patient outcome associated with JAK1 mutations and the transcriptomic subgroup CMS1
a causal relationship between MLH1 (show MLH1 Antibodies)-deficiency and incidence of oncogenic point mutations in tyrosine kinases driving cell transformation and acquired resistance to kinase-targeted cancer therapies, is reported.
Data show that moringin (GMG-ITC) had a limited inhibitory effect on IFNalpha-induced STAT1 (show STAT1 Antibodies) and STAT2 (show STAT2 Antibodies) activity, indicating differentially targeting JAK (show JAK3 Antibodies)/STAT (show STAT1 Antibodies) signaling pathways.
our studies highlight Jak1 as the first identified substrate for USP6 (show USP6 Antibodies), and they offer a mechanistic rationale for the clinical investigation of Jak (show JAK3 Antibodies) and STAT3 (show STAT3 Antibodies) inhibitors as therapeutics for the treatment of bone and soft tissue tumors along with other neoplasms driven by USP6 (show USP6 Antibodies) overexpression
In this structure, the receptor peptide forms an 85-A-long extended chain, in which both the previously identified box1 and box2 regions bind simultaneously to the FERM and SH2-like domains of JAK1.
JAK1-mediated signaling cascades in skin regulate the expression of proteases associated with the maintenance of skin barrier function and demonstrate that perturbation of these pathways can lead to the development of spontaneous pruritic dermatitis.
Small-scale in vivo screening identified several genes, including Cd109 (show CD109 Antibodies), that encode novel pro-metastatic factors. We uncovered signaling mediated by Janus kinases (Jaks) and the transcription factor Stat3 (show STAT3 Antibodies) as a critical, pharmacologically targetable effector of CD109 (show CD109 Antibodies)-driven lung cancer metastasis
High JAK1 expression is associated with Hepatic Fibrosis.
findings demonstrate that clinically relevant doses of the JAK1/2 inhibitor ruxolitinib suppresses the harmful consequences of macrophage overactivation characterizing Hemophagocytic lymphohistiocytosis in 2 murine models.
Data show that CUZD1 (show CUZD1 Antibodies) interacts with a complex containing JAK1/JAK2 (show JAK2 Antibodies) and STAT5 (show STAT5A Antibodies), downstream transducers of prolactin (show PRL Antibodies) signaling in the mammary gland.
JAK1 conditional knockout mice will be an invaluable tool to study cytokine signaling during normal development and disease progression in adult animals.
JAK1, JAK2 (show JAK2 Antibodies), and JAK3 (show JAK3 Antibodies) are involved in stimulation of functional activity of mesenchymal progenitor cells by fibroblast growth factor.
JAK (show JAK3 Antibodies) mediated signaling is involved in the differentiation and proliferation of mesenchymal progenitor cells.
Data indicate thar Janus kinase 1 (Jak1) degradation is dependent on Nedd4 family interacting proteins Ndfip1 (show NDFIP1 Antibodies)/Ndfip2 (show NDFIP2 Antibodies).
JAK1 activating mutants are insufficient to drive hepatocellular carcinoma development in vivo.
Janus kinase 1 (JAK1), is a member of a new class of protein-tyrosine kinases (PTK) characterized by the presence of a second phosphotransferase-related domain immediately N-terminal to the PTK domain. The second phosphotransferase domain bears all the hallmarks of a protein kinase, although its structure differs significantly from that of the PTK and threonine/serine kinase family members. JAK1 is a large, widely expressed membrane-associated phosphoprotein. JAK1 is involved in the interferon-alpha/beta and -gamma signal transduction pathways. The reciprocal interdependence between JAK1 and TYK2 activities in the interferon-alpha pathway, and between JAK1 and JAK2 in the interferon-gamma pathway, may reflect a requirement for these kinases in the correct assembly of interferon receptor complexes. These kinases couple cytokine ligand binding to tyrosine phosphorylation of various known signaling proteins and of a unique family of transcription factors termed the signal transducers and activators of transcription, or STATs.
tyrosine-protein kinase JAK1
, jak1 kinase
, Janus protein tyrosine kinase 1
, Janus kinase 1 (a protein tyrosine kinase)
, tyrosine kinase JAK1
, janus kinase 1
, protein tyrosine kinase
, Janus kinase 1
, Tyrosine-protein kinase Jak1
, tyrosine-protein kinase JAK1-like